Promising data from the Bcl-2 inhibitor GDC-0199/ABT-199 in hematology presented at ASCO

Late stage development underway in chronic lymphocytic leukemia. Roche today announced promising phase 1 data from a study of GDC-0199/ABT-199, also known as RG7601, in people with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Data were presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Relapsed cancer refers to a cancer that returns after a period of remission while refractory cancer refers to a cancer that is no longer responding to treatment.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news